

Anil Abraham Joy

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9193005/anil-abraham-joy-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

438
citations

7
h-index

20
g-index

21
ext. papers

564
ext. citations

5.2
avg, IF

2.27
L-index

#	Paper	IF	Citations
21	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1688-1700	21.7	328
20	Community-based exercise for health promotion and secondary cancer prevention in Canada: protocol for a hybrid effectiveness-implementation study. <i>BMJ Open</i> , 2019 , 9, e029975	3	22
19	A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2021 , 142, 132-140	7.5	20
18	The "Begin Exploring Fertility Options, Risks and Expectations" (BEFORE) decision aid: development and alpha testing of a fertility tool for premenopausal breast cancer patients. <i>BMC Medical Informatics and Decision Making</i> , 2019 , 19, 203	3.6	12
17	Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial. <i>BMJ Open</i> , 2019 , 9, e030502	3	12
16	Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 93-101	4.4	10
15	Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019 , 10, 1070-1082	10.3	10
14	A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11501-11501	2.2	6
13	Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359211066677	5.4	5
12	Targeting HER2 in Advanced Breast Cancer. <i>Methods in Molecular Biology</i> , 2017 , 1652, 63-77	1.4	3
11	Genome profiles of lymphovascular breast cancer cells reveal multiple clonally differentiated outcomes with multi-regional LCM and G&T-seq		2
10	Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials. <i>Supportive Care in Cancer</i> , 2019 , 27, 1551-1561	3.9	2
9	Optimising weight-loss interventions in cancer patients-A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2021 , 16, e0245794	3.7	2
8	Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. <i>Journal of Bone Oncology</i> , 2021 , 30, 100388	4.5	2
7	Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021 , 28, 1847-1856	2.8	1
6	Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.. <i>Current Oncology</i> , 2022 , 29, 2720-2734	2.8	1
5	Genome profiles of pathologist-defined cell clusters by multiregional LCM and G&T-seq in one triple-negative breast cancer patient. <i>Cell Reports Medicine</i> , 2021 , 2, 100404	18	0

- 4 Weight control strategies in breast cancer patients: A systematic review.. *Journal of Clinical Oncology*, **2016**, 34, 179-179 2.2
- 3 A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer.. *Journal of Clinical Oncology*, **2016**, 34, e21594-e21594 2.2
- 2 Assessing the need for a nurse-led breast cancer telephone follow-up clinic in Alberta, Canada.. *Journal of Clinical Oncology*, **2013**, 31, 111-111 2.2
- 1 Why "Reply All" Can Push All the Wrong Buttons. *Oncologist*, **2019**, 24, e643-e645 5.7